Amwell Q2 2026 revenue falls to $52.0 million; net loss narrows to $9.6 million
Amwell reported second-quarter 2026 revenue of $52.0 million, down from $70.9 million a year earlier, while its net loss narrowed to $9.6 million from $19.5 million. It raised the low end of its 2026 revenue outlook and narrowed its adjusted EBITDA loss forecast, but guided third-quarter revenue to $46 million to $48 million, below the second quarter level. For shareholders, the filing shows smaller losses and higher guidance alongside a year-over-year revenue decline.
Key points
- Q2 2026 revenue was $52.0 million versus $70.9 million in Q2 2025; net loss was $9.6 million versus $19.5 million.
- Adjusted EBITDA was a loss of $1.2 million, compared with a loss of $3.1 million in Q1 2026.
- 2026 revenue outlook is $200 million to $205 million, with the low end raised from $195 million; adjusted EBITDA outlook improved to a loss of $7 million to $9 million from a loss of $12 million to $16 million.
- Q3 2026 revenue guidance is $46 million to $48 million; the company reiterated its target of positive operating cash flow in Q4 2026.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.